Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity PharmaTimesLatebreaking EULAR results highlight sustained responses through week 52Immunology & InflammationRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) PharmaTimes Latebreaking EULAR results highlight sustained responses through week 52 Immunology & Inflammation Read full story Post navigation Previous: Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnershipNext: Alnylam hops on AI train with up to $2B Inceptive partnership Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026